| 產(chǎn)品編號 | bs-0037R |
| 英文名稱 | AIF Rabbit pAb |
| 中文名稱 | 凋亡誘導因子抗體 |
| 別 名 | Apoptosis inducing factor; Harlequin; Hq; mAIF; MGC111425; MGC5706; PDCD 8; PDCD8; Programmed cell death 8; Programmed cell death 8 isoform 1; Programmed cell death 8 isoform 2; Programmed cell death 8 isoform 3; Programmed cell death protein 8 mitochondrial; Programmed cell death protein 8 mitochondrial precursor; Striatal apoptosis inducing factor; AIFM1_HUMAN; Apoptosis-inducing factor 1, mitochondrial. |
 |
Specific References (11) | bs-0037R has been referenced in 11 publications.
|
| 研究領域 | 腫瘤 細胞生物 染色質(zhì)和核信號 神經(jīng)生物學 細胞凋亡 細胞周期蛋白 線粒體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat,Pig (predicted: Rabbit,Sheep,Cow,Chicken,Dog) |
| 產(chǎn)品應用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 57 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 線粒體 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human AIF: 131-230/613 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a flavoprotein essential for nuclear disassembly in apoptotic cells, and it is found in the mitochondrial intermembrane space in healthy cells. Induction of apoptosis results in the translocation of this protein to the nucleus where it affects chromosome condensation and fragmentation. In addition, this gene product induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. Mutations in this gene cause combined oxidative phosphorylation deficiency 6, which results in a severe mitochondrial encephalomyopathy. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 10. [provided by RefSeq, May 2010]. Function: Probable oxidoreductase that has a dual role in controlling cellular life and death; during apoptosis, it is translocated from the mitochondria to the nucleus to function as a proapoptotic factor in a caspase-independent pathway, while in normal mitochondria, it functions as an antiapoptotic factor via its oxidoreductase activity. The soluble form (AIFsol) found in the nucleus induces 'parthanatos' i.e. caspase-independent fragmentation of chromosomal DNA. Interacts with EIF3G,and thereby inhibits the EIF3 machinery and protein synthesis, and activates casapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposed cells. Binds to DNA in a sequence-independent manner. Subunit: Interacts with XIAP/BIRC4. Interacts (via N-terminus) with EIF3G (via C-terminus). Subcellular Location: Mitochondrion intermembrane space. Mitochondrion inner membrane. Cytoplasm. Nucleus. Cytoplasm, perinuclear region. Note=Proteolytic cleavage during or just after translocation into the mitochondrial intermembrane space (IMS) results in the formation of an inner-membrane-anchored mature form (AIFmit). During apoptosis, further proteolytic processing leads to a mature form, which is confined to the mitochondrial IMS in a soluble form (AIFsol). AIFsol is released to the cytoplasm in response to specific death signals, and translocated to the nucleus, where it induces nuclear apoptosis. Colocalizes with EIF3G in the nucleus and perinuclear region. Tissue Specificity: Isoform 5 is frequently down-regulated in human cancers. Post-translational modifications: Under normal conditions, a 54-residue N-terminal segment is first proteolytically removed during or just after translocation into the mitochondrial intermembrane space (IMS) by the mitochondrial processing peptidase (MPP) to form the inner-membrane-anchored mature form (AIFmit). During apoptosis, it is further proteolytically processed at amino-acid position 101 leading to the generation of the mature form, which is confined to the mitochondrial IMS in a soluble form (AIFsol). AIFsol is released to the cytoplasm in response to specific death signals, and translocated to the nucleus, where it induces nuclear apoptosis in a caspase-independent manner. Ubiquitination by XIAP/BIRC4 does not lead to proteasomal degradation. Ubiquitination at Lys-255 by XIAP/BIRC4 blocks its ability to bind DNA and induce chromatin degradation, thereby inhibiting its ability to induce cell death. DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6) [MIM:300816]: A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the FAD-dependent oxidoreductase family. SWISS: O95831 Gene ID: 9131 Database links: Entrez Gene: 51060 Human Entrez Gene: 9131 Human Entrez Gene: 26926 Mouse Omim: 300169 Human SwissProt: O95831 Human SwissProt: Q9Z0X1 Mouse AIF是一種易位到細胞核誘導凋亡的線粒體蛋白, AIF可引起DNA破碎、染色質(zhì)凝聚，還可誘導細胞色素C和Caspase-9從線粒體中釋放出來，AIF從線粒體中的釋放可被過度表達的Bcl-2（一種參與線粒體滲透的蛋白質(zhì)）所抑制。 |
| 產(chǎn)品圖片 |
Sample:
Liver (Mouse) Lysate at 40 ug
Primary: Anti-AIF (bs- 0037R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57 kD
Observed band size: 63 kD
Sample:
Lane 1: K562 (Human) Cell Lysate at 30 ug
Lane 2: Testis (Rat) Lysate at 40 ug
Lane 3: Testis (Mouse) Lysate at 40 ug
Primary: Anti-AIF (bs-0037R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 67’62’57 kD
Observed band size: 62 kD
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
